Around the Web — 4.18.23
The emerging SARS-CoV-2 subvariant XBB.1.16 may carry the previously rare symptom of conjunctivitis, according to a pediatrician in India and a news report in the
The emerging SARS-CoV-2 subvariant XBB.1.16 may carry the previously rare symptom of conjunctivitis, according to a pediatrician in India and a news report in the
FDA announced yesterday it is requiring manufacturers of opioid analgesics dispensed in outpatient settings to make prepaid mail-back envelopes available to outpatient pharmacies and other
FDA yesterday approved Emergent BioSolutions’ Narcan (naloxone hydrochloride) 4 mg nasal spray for OTC use. The action “paves the way for the life-saving medication to
Children 6 months to 4 years of age are now eligible to receive a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, as a
The FDA has unveiled its new Dietary Supplement Ingredient Directory, a webpage where the public can look up ingredients used in products marketed as dietary
The 2022–23 influenza vaccine has provided reasonable protection against infection and hospitalization caused by infection, members of the CDC’s Advisory Committee on Immunization Practices heard
FDA on Friday granted accelerated approval to sparsentan (Filspari, Travere Therapeutics) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid
FDA last week approved velmanase alfa (Lamzede), the first enzyme replacement therapy approved in the U.S. for the treatment of non-central nervous system manifestations of alpha-mannosidosis,
With the federal public health emergency ending on May 11, the U.S. Department of Health and Human Services has released a “transition roadmap” that discusses
The FDA last week dropped the emergency use authorization requirement that patients have positive test results before prescribing of the antiviral products ritonavir-boosted nirmatrelvir (Paxlovid)